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We exploited the fact that leukemic cells utilize significantly
higher levels of S-adenosylmethionine (SAMe) than normal
lymphocytes and developed tools that selectively diminished
their survival under physiologic conditions. Using RNA inter-
ference gene silencing technology, wemodulated the kinetics of
methionine adenosyltransferase-II (MAT-II), which catalyzes
SAMe synthesis from ATP and L-Met. Specifically, we silenced
the expression of the regulatoryMAT-II subunit in Jurkat cells
and accordingly shifted the Km L-Met of the enzyme 10–15-fold
above the physiologic levels of L-Met, thereby reducing enzyme
activity and SAMe pools, inducing excessive apoptosis and
diminishing leukemic cell growth in vitro and in vivo. These
effects were reversed at unphysiologically high L-Met (>50 M),
indicating that diminished leukemic cell growth at physiologic
L-Met levels was a direct result of the increase in MAT-II
Km L-Met due toMAT-II ablation and the consequent reduction
in SAMe synthesis. In our NOD/Scid IL-2Rnull humanized
mouse model of leukemia, control shRNA-transduced Jurkat
cells exhibited heightened engraftment, whereas cells lacking
MAT-II failed to engraft for up to 5 weeks post-transplant.
These stark differences in malignant cell survival, effected by
MAT-II ablation, suggest that it may be possible to use this
approach to disadvantage leukemic cell survival in vivowith lit-
tle to no harm to normal cells.
Leukemia are among the deadliest and most common can-
cers. Despite advancements in novel individual and combina-
tion drug treatment modalities, mortality rates remain high,
and some medications have serious adverse effects (2, 3). Our
goal has been to develop novel approaches that exploit physio-
logical differences in metabolic needs between normal and leu-
kemic cells to generate tools that would selectively diminish
tumor cell growth in vivo, with minimal harm to normal host
cells. Specifically, we sought to exploit significant differences in
S-adenosylmethionine (SAMe)2 metabolism between normal
and leukemic T cells (4, 5). SAMe is an essential molecule in the
metabolism of every living species (6–10). As the main methyl
group donor, it methylates DNA, RNA, fatty acids, proteins,
and small molecules and regulates several transcription and
translation processes, protein function, and membrane integ-
rity. SAMe is also involved inDNAmismatch repair, chromatin
modeling, epigenetic modifications and imprinting, cell repli-
cation, neurotransmission, and signaling (11). Additionally,
SAMe is an important precursor of the polyamines and amajor
player in biological trans-sulfuration as well as folic acid and
one-carbon metabolism (8, 9, 11, 12).
The importance of SAMe, together with the fact that its
metabolism is constitutively elevated in malignant versus nor-
mal cells, has for years made it an attractive target for cancer
chemotherapy (13–20). Unfortunately, chemical inhibitors of
SAMe synthesis have been difficult to generate in quantities
needed for clinical use, and most were either unstable, reversi-
ble, nonspecific, or highly toxic because no cell can survive total
inhibition of SAMe synthesis. To this end, our approach has
been to take advantage of the dependence on higher SAMe
levels in leukemic cells to diminish rather than totally block
their ability to synthesize the needed amount of SAMe and
thereby selectively halt their growth while sparing normal cells.
The advent of novel biotools that can selectively silence pro-
tein expression has made it possible to initiate studies to target
the regulatory subunit of methionine adenosyltransferase
(MAT), which catalyzes the synthesis of SAMe from L-Met and
ATP. All living organisms have at least one MAT enzyme (5,
13). Mammals have liver-specific MAT-I/III and another
isozyme,MAT-II, that is expressed in all tissues (21, 22). MAT-
I/III are tetramer/dimer forms of a catalytic 1 subunit, and
they differ considerably in their kinetic and physical properties.
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It is believed that this differential oligomerization ofMAT-1 is
an important adaptation to cope with special metabolic
requirements in the liver, where SAMe levels need to be main-
tained at a certain range inasmuch as a deficiency or excess of
SAMe has been associated with serious pathology (23–25). In
livers of healthy subjects, MAT-III, which has a high Km L-Met
(80–100 M), is the major isoform. By contrast, MAT-II is a
hetero-oligomer that has a catalytic2 subunit and a regulatory
 subunit with a Km L-Met of 4–20 M (21, 26, 50). The 2 sub-
unit, which has 84% sequence identity to 1, undergoes post-
translational modifications resulting in expression of 2 (53
kDa) and2 (51 kDa) forms (21). In fetal liver and certain adult
liver diseases, including hepatocellular carcinoma, 1 subunit
expression is diminished and replaced by 2, along with the
induction of MAT-II expression (27, 28).
MAT- subunits are highly conserved across many species
(22); by contrast MAT-II is only found in mammals, associ-
ated with MAT-II2. In several of our previous studies, we
showed thatMAT-II plays a crucial physiological role by low-
ering the Km of MAT-II for L-Met from 55–65 M down to
3.5–20 M (26, 29, 50). Inasmuch as the physiologic extrahe-
patic concentration of L-Met are 5–10-fold lower than that in
the liver (30), we believe that the introduction of MAT-II to
lower the Km of the extrahepatic enzyme may have been an
essential evolutionary event that allowedMAT-II to function in
blood and other extrahepatic mammalian tissues, where L-Met
levels are 10–25 M (31–33).
We had reported that MAT-II expression and SAMemetab-
olism are considerably different in normal and malignant lym-
phocytes (4, 5, 8). MAT-II expression in established and pri-
mary human lymphocytic leukemia cells is significantly higher
than in quiescent or activated lymphocytes (4).MAT-II activity,
SAMe utilization rate, and SAMe pool size are, respectively,
20-, 60-, and 60–100-fold higher in lymphocytic leukemia, than
in normal lymphocytes (4). Based on these previous studies (4,
21, 26, 29), we predicted that if we specifically ablatedMAT-II
expression, we would shift MAT-II Km L-Met by at least 10-fold
above physiologic L-Met levels, and that this would conse-
quently reduce SAMe pool size and selectively diminish the
growth of leukemic cells in physiological fluids and extrahe-
patic tissues. We report that MAT-II subunit specific shRNA
successfully silenced the expression of theMAT-II regulatory
subunit in the Jurkat leukemic T cell line and increased the
enzyme Km L-Met by 10–15-fold, consequently depleting SAMe
pools, inducing excessive apoptosis, and diminishing the
growth of these leukemic cells in physiologic L-Met concentra-
tions, both in vitro and in vivo in a humanized NOD/Scid
IL-2Rnull mouse model of leukemia.
EXPERIMENTAL PROCEDURES
Leukemic Cells—Jurkat T cells (E6–1; ATCC,Manassas, VA)
were maintained in RPMI 1640 medium, supplemented with
either 10% fetal bovine serum or 1% HL-1 supplement (L-
Met), 2 mM L-glutamine, 50 g/ml streptomycin, and 50
units/ml of penicillin.
Generation of pHSPG-shRNA Retrovirus—We designed sev-
eral shRNA sequences to target MAT-II expression and
BLAST-searched these sequences against the human genome
data base to ensure their specificity for our target gene. The
pHSPG plasmid (Dr. Su, University of North Carolina) has a
constitutively active polymerase III promoter in front of the
multiple cloning site. We modified pHSPG by including a His-
tone 1 promoter needed for shRNA formation (34), followed by
shRNA constructs of interest between the EcoRV and XbaI
sites, in themultiple cloning site. Downstream of this construct
is a PGK-GFP cassette whose expression is driven by themouse
mammary tumor virus promoter. The HSPG virus was chosen
for its high transduction efficiency in hematopoetic cells (36,
37). The design of different MAT-II-specific pHSPG-shRNA
drivenby theHistone1promoter is showninsupplementalFig.S1.
The effect of several control and MAT-II-specific pHSGP-
shRNA constructs onMAT-II expression were initially tested
in transiently transfected Cos-1 cells. These studies showed
that plasmid pHSGP-shRNA-1110 had the highest gene silenc-
ing activity and was not toxic to the Cos-1 cells, and thus we
packaged it into HSPG-V1110 viral particles using HEK-293T
cells and the CaCl2 transfection method (35). We also gener-
ated a control, empty virus without shRNA (V1302) and V1324
that encodes an shRNA for an irrelevant, mouse plexin A1 gene
(37).
Transduction with HSPG-shRNA Retrovirus—We trans-
duced Jurkat cells (106 cells) by adding 8 mg/ml polybrene plus
700 ml of viral supernatants and incubating for 20 min at room
temperature. The cells were spun at 2000 rpm for 3 h and then
resuspended in fresh 1.5 ml of RPMI 1640 complete medium.
We cultured the cells in 12-well tissue culture plates, repeated
the transduction after 24 and/or 48 h, and then assessed trans-
duction efficiency by flow cytometry (FACSCalibur) to deter-
mine the percentage of GFP-positive cells. This procedure typ-
ically yielded 90% GFP cells, which were then sorted using
FACSAria (BD Biosciences) to obtain a 98% transduced cell
population.
MAT-II Subunits Expression Analysis—We lysed GFP
sorted cells by three cycles of freeze-thawing in extraction
buffer (50 mM Tris, pH 7.4, 50 mM NaCl, 5 mM MgCl2, 4 mM
dithiothreitol), containing a mixture of proteolytic inhibitors
(Roche Applied Science) as described (5). Protein concentra-
tion was determined in the cleared lysates by the bicinchoninic
acid method (38). Equal amounts of protein extracts were sep-
arated on 10% SDS-PAGE and then transblotted onto nitrocel-
lulose papers. Expression of 2 and  subunits was determined
by Western blots and probed with antibodies to MAT-II and
MAT-II proteins (4, 39).
We also used quantitative real time PCR to assess MAT-
II and MAT-II mRNA expression. We constructed cRNA
standards for each subunit and generated standard curves
for each run to quantify mRNA copy number/2 g of total
RNA. Briefly, we transformed Escherichia coli strain JM109
with pTargeT/MAT-II subunit or pTargeT/MAT-II
subunit (26) and purified those plasmids using the Wizard
PureFection DNA purification system (Promega). Correct
pTargeT/MAT-II and pTargeT/MAT-II plasmids were
verified by sequencing, using a T7 promoter primer. T7
Ribomax large scale RNA production system (Promega) was
used to generate MAT-II or MAT-II cRNA. The number
of cRNAmolecules were calculated as follows: N(molecules/
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l)  [C*1825  1013]/K, where C  cRNA g/l and K 
bp (40). For MAT-II cRNA, K  1188 bp and C  0.658
g/l; for MAT-II cRNA, K  1050 bp and C  0.632.
To test the efficiency of MAT-II silencing, we extracted
RNA from 106 untransduced or transduced cells using RNA-
STAT 60 (Tel-Test), removed residual contaminating genomic
DNA by DNase I treatment (Qiagen), purified the RNA using
Qiagen RNeasy kit, and then converted 2 g of the purified
RNA to cDNA using avian myeloblastosis virus reverse tran-
scriptase, 10 randomhexamers, and 10mMdNTP in the pres-
ence of RNase inhibitor (Promega). Quantitative real time
PCRs were run using the fluorogenic SYBR Green quantitative
real time PCR system and the ABI prism 7900 Sequence Bio-
Detector (PE Biosystems). In each run, serial dilutions ofMAT-
II or MAT-II cRNA (104–1010 cRNA molecules/l) were
also converted to cDNA and used to generate the standard
curve for eachMAT-II subunit. The PCRmixture contained 25
l of SYBRGreen PCRMastermix (Applied Biosystems), 2.5l
containing 1.5–12 pmol of each primer, and 5l of the template
cDNA in a final volume of 50 l. The sequence of theMAT-II
specific primers were (forward, 5-CACCTTACAGAGAGGA-
AGA-3 and reverse, 5-CAGTCACAGCACTTTCTTC-3);
and forMAT-II2 specific primers (forward, 5-AAAGTGGT-
TCGTGAAGCTGTTAAA-3 and reverse, 5-CCAAGGCTA-
CCAGCACGTTAC-3). An 18 S RNA primer mix (Qiagen)
was used for normalization. To calculateN for each test sample,
we first normalized the cycle threshold (CT) to the internal
normalizer (18 S) and then determined N from the standard
curve using the equation Y  [MX  C].
Assay for MAT Activity—We assayed MAT activity in cell
extracts as described previously (21). For kinetic analyses, we
used different L-Met concentrations (1.25–80 M), using
[14C]L-Met (57.9 mCi/mmol) and supplementing with cold
L-Met. Reaction velocity is expressed as units/mg protein,
where 1 unit  1 nmol of adenosylmethionine/h (21). We cal-
culated Km and Vmax using the GraphPad Prism program.
Cell Growth at Different L-Met Concentrations—We weaned
the cells to grow in serum-free RPMI 1640 medium containing
1%HL-1 supplement (Cambrex, NJ) plus 2 mM L-glutamine, 50
g/ml streptomycin, and 50 units/ml of penicillin (RPMI-HL1s
medium). We seeded weaned cells (106/ml) in RPMI-HL1s
medium at L-Met 5–100M, replaced themedium every 2 days,
recorded numbers of viable cells, and then replated the cells at
106/ml for further analyses. Cell necrosis and apoptosis were
determined by a flow cytometric quantification of propidium
iodide and annexin-V (BD Pharmingen) stained cells, respec-
tively. In some studies, the cells were cultured at 10 M L-Met
for 3d, harvested, counted, and replated at 106 cells/ml in fresh
RPMI-HL1smediumwith 10ML-Met.Onday 6, the cellswere
harvested, washed, and replated in freshmedium containing 20
M or 50 M L-Met. The cell growth/death were determined
every 3 days thereafter, replating 106 viable cells/ml each time.
Measurement of SAMe Levels—We quantified SAMe levels in
a neutralized 2 N perchloric acid-soluble extract by HPLC as pre-
viously detailed (4). We calculated the SAMe concentration
(pmol/106 cells) from a standard curve using different concentra-
tions of SAMe standard (USB Corp.) and then converted the val-
ues toMbasedoncell volume for Jurkat cells 0.76ml/109 cells (4).
In Vivo Animal Studies—All of the animals were treated
according to Institutional Animal Care and Use Committee
regulations (protocol 1587).We irradiated highly immune defi-
cient NOD/ScidIL-2Rnull mice with 3.5GY, 24 h prior to
transplanting them via intraperitoneal injection of 15  106
V1110 or V1302 Jurkat cells. We obtained sera from mice 12
days post-injection and then once a week thereafter to quantify
levels of the surrogate tumormarker, soluble2microglobulin,
using an enzyme-linked immunosorbent assay 2 microglobu-
lin kit (R & D). At 4 and 5 weeks post-transplant, we sacrificed
the transplanted mice (supplemental Table S1) and used fluo-
rescence reflectance imaging to image GFP fluorescence in
spleen prior to extracting splenocytes and bonemarrow cells to
assess tumor growth and engraftment by counting % human
CD3/GFP-positive cells in each compartment by flow cytom-
etry as detailed above.
Statistical Methods—We calculated statistical significance
with one-way analysis of variance andNewman-KeulsMultiple
Comparison test for all the experiments except for the in vivo
experiment where we used a Mann-Whitney test using the
GraphPad Prism program.
RESULTS
Successful Ablation of MAT-II Expression—We designed
several shRNA to ablateMAT-II expression, cloned them into
the retroviral plasmid pHSPG, which also expresses GFP, and
screened their gene silencing efficiency and nonspecific toxicity
(supplemental Fig. S1). All MAT-II-specific shRNA con-
structs were designed to target the two splice variants of MAT-
II (28). Initial screening was done in COS-1 cells, and con-
structs with efficient gene silencing activity were then screened
in Jurkat cells (supplemental Fig. S1). Construct V1110 had the
highest MAT-II silencing activity (supplemental Fig. S1) and
least toxicity and was thus packaged into infectious HSPG-GFP
virus (36).
We transduced Jurkat cells with the various recombinant
HSPG-shRNA viruses and assessed MAT-II ablation at the
RNA and protein levels (supplemental Fig. S1). Controls
included cells infectedwith an empty virus (V1302) orwith a virus
encoding shRNA construct (V1324) directed to the mouse plexin
A1 gene (36). Although transduction efficiencies for all cells tested
were 90%, significant reduction or complete ablation of MAT-
II RNA and protein expression was only seen in V1110-trans-
duced cells (Fig. 1). By contrast, expression of MAT-II2 was
essentially unaffected, thus indicating the MAT-II specificity of
V1110. In some cases, expression ofMAT-II2was insignificantly
elevated,perhaps reflectinganattempt to increaseenzymesynthe-
sis to compensate for the lack of  expression and increase SAMe
synthesis.
Effect of MAT-II Silencing on MAT-II Activity, Kinetics,
SAMePool Size, andCellularGrowth—Wenext testedwhether
ablation ofMAT-II expression will alterMAT-IIKm L-Met and
reduce SAMe pools in Jurkat cells. As predicted, the Km L-Met
increased from 3.5–6 M in untransduced and control virus-
transduced Jurkat cells, up to 56–62 M in V1110 cells (Fig.
2A). Further, at the high end of physiological L-Met levels (20
M),MAT-II specific activity was 4–5-fold lower inV1110 cells
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than in untransduced or control virus-transduced Jurkat cells
expressing MAT-II (Fig. 2B).
Importantly, in the absence of MAT-II, SAMe was unde-
tectable in V1110 cells cultured at 10 M L-Met (not shown),
and even at 20 M L-Met SAMe pool size was85% less than in
untransduced or control-transduced V1302 cells (9.5  0.5 M
versus 62  4 M; p  0.05) (Fig. 2C). Significant 45–50%,
reductions in SAMe pool size (p  0.01) were also found even
when V1110 cells were maintained at 50 M L-Met, which is
2.5-fold higher than the upper range of physiological L-Met
levels.
The sharp reduction in SAMepool size, consequent toMAT-
II ablation, diminished the growth and viability of V1110 cells.
At 20 M L-Met, V1110 cells ceased to grow, and at 50 M
their growth was reduced by 33–36% compared with control-
transduced V1302 cells (p  0.01) (Fig. 3). By contrast, at 100
M L-Met, V1110 cells grew at essentially the same rates and for
the same duration in culture as the untransduced or control-
transduced Jurkat cells (p  0.05) (Fig. 3). Thus, at unphysi-
ologically high L-Met levels approaching MAT-II2 Km with-
out  (i.e. Km  50–60 M), V1110 leukemic cells appear to
have satisfied their SAMe needs and grew normally. These
results indicate that diminished
V1110 cell growth at physiologic
L-Met levels was a direct conse-
quence of specific MAT-II silenc-
ing, which caused an upper shift in
Km L-Met ofMAT-II and a significant
reduction of SAMe synthesis and
pools.
Cell Death and Apoptosis of Leu-
kemic Cells Lacking MAT-II—Sig-
nificant reduction in growth rates of
V1110 cells at physiological L-Met
levels was associated with a signifi-
cant increase in both cell necrosis
and apoptosis (Fig. 4). At physio-
logic L-Met levels (5, 10, and 20M),
the extent of necrosis in the V1110
cells was significantly higher (20–
55%) than in untransduced or con-
trol V1302 cells (p  0.001). Mini-
mal cell death was seen at 50 M
L-Met; however, V1110 cells exhib-
ited 70–80% higher levels of apo-
ptosis than the control leukemic
cells even at this unphysiological
L-Met concentration (p 0.01) (Fig.
4). This is likely attributed to the
50% reduction in SAMe pool size
even at 50 M L-Met (Fig. 2). Taken
together, these findings indicate
that the growth and viability of
V1110 cells lacking MAT-II
expression remained at a selective
disadvantage, even at more than
twice the higher end of physiologi-
cal L-Met levels.
FIGURE 1. Successful ablation of MAT-II subunit using viral encoded
shRNA. MAT-II 2 and  protein expression (60 g of protein/well) and mRNA
levels were analyzed in untransduced or 98% transduced cells as detailed
under “Experimental Procedures.” Quantitative real time PCR was conducted
using RNA extracted from cells maintained in 100 M L-Met RPMI medium, and
RNA copy number was calculated as detailed under “Experimental Procedures.”
The results (means  S.E.) of two combined experiments, each done in triplicate,
are shown. Statistical differences were determined as described under “Experi-
mental Procedures.” MAT-II expression was significantly ablated in V1110 cells.
***, p  0.001. MAT-II2 was slightly elevated or unaffected (p  0.05).
FIGURE 2. MAT-II ablation modulates MAT-II kinetics, reduces its specific activity, and diminishes intra-
cellular SAMe levels. A, MAT-II Lineweaver-Burk kinetic plots of 1/V, where V is units of enzyme activity/mg of
protein (units/mg; 1 unit  1 nmol of adenosylmethionine/h). MAT assays were performed using extracts from
untransduced, V110- or V1302-transduced cells in the presence of 2.5– 80 M L-Met, as detailed under “Exper-
imental Procedures.” The data for each cell extract represents the means  S.D. of three separate experiments,
each assayed in triplicate. B, MAT specific activity (units/mg of protein) at 20 M L-Met. C, SAMe levels (pmol/106
cells) as determined by HPLC in neutralized perchloric acid extracts from cells that were maintained at 50 or 20
M L-Met. *, p  0.05; **, p  0.01; ***, p  0.001.
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Attempts to Rescue Cells by Incrementally Elevating L-Met
Levels—Following up on selective pressure imposed on the via-
bility of MAT-II-deficient Jurkat cells in physiologic L-Met
conditions, we next tested whether V1110 cells can be rescued
by incremental elevation of L-Met in culture. All of the cells
grew at lower rates at the low end (5–10 M) of physiologic
L-Met levels compared with 20 M.We therefore maintained
V1110 and control Jurkat cells at 10 M L-Met for 6 days in
culture and then increased L-Met levels to either 20 or 50 M to
determine whether these cells can be rescued (Fig. 5). The
growth of control untransduced and control V1302 Jurkat cells
increased by almost 80 and 90% when L-Met levels were raised
to 20 or 50 M, respectively. By contrast, under the same con-
ditions, V1110 cells could not be rescuedwith 20ML-Met (p
0.01) and exhibited diminished growth even at 50 M L-Met
(p  0.05) (Fig. 5). These data suggest that the initial insult to
the V1110 cells, caused by low SAMe levels due to the absence
ofMAT-II, is irreversible at the high end of physiologic L-Met
levels (20 M) andminimally reversible at 50 M L-Met. Failure
to rescue V1110 cells is consistent with the above observed
increased apoptosis of these cells, even at 50 M L-Met (Fig. 4).
MAT-II Ablation Diminishes Leukemic Cell Growth in an
NOD/Scid IL-2Rnull Mouse Leukemia Model—To rule out
possible in vitro culture artifacts, we investigated whether Jur-
kat cells that do not express MAT-II would survive and mul-
tiply in vivo in our severely immunodeficient NOD/Scid
IL-2Rnull mouse model (41). These mice allow heightened
engraftment with xenogeneic cells because, besides lacking T,
B, and NK cells, they are also defi-
cient in complement and macro-
phage function (41). After mildly
irradiating these mice, we trans-
planted them intraperitoneally with
15  106 V1110 or control V1302
cells (n  15 mice/group). Irradi-
ated, noninjected mice served as
additional controls. We monitored
tumor engraftment and growth
weekly for 5 weeks post-transplant
by determining the percentage of
human CD3 and GFP expression in
bone marrow (BM)- and spleen-de-
rived cells and by measuring serum
levels of the surrogate tumor
marker, 2-microglobulin (2)
(42). We also imaged GFP expres-
sion in whole spleens of sacrificed
mice for a semi-quantitative meas-
ure of tumor burden (Fig. 6).
During the first 3 weeks, none of
the transplanted mice showed sig-
nificant engraftment, but after 4
weeks, 57% of mice transplanted
with control V1302 cells began to
show variable levels of engraftment
in spleen (3–44% human CD3/
GFP cells; mean 16  7.6%) and in
BM (3–12% human CD3/GFP
FIGURE 3. MAT-II ablation reduces leukemic cell growth in physio-
logic L-Met levels. We seeded 5  106 of indicated cells at 5–100 M L-Met
and monitored their growth every 2 days using the trypan blue exclusion
method, adding fresh medium each time. *, p  0.05; **, p  0.01; ***, p 
0.001.
FIGURE 4. MAT-II ablation induces high levels of apoptosis and necrosis of leukemic cells. A, propidium
iodide-stained necrotic cells (%) at 20 M L-Met. B, propidium iodide-stained necrotic cells (%) at 50 M L-Met.
C, necrotic cells (%) at 6 days in 5–50 M L-Met. D, annexin-V-stained apoptotic cells (%) at 20 M L-Met.
D, annexin-V stained apoptotic cells (%) at 50 M L-Met. F, apoptotic cells (%) at 6 days in 5–50 M L-Met. *, p 
0.05; **, p  0.01; ***, p  0.001.
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cells; mean 4  1.6%). Engraftment was much less evident in
spleens of mice transplanted 4 weeks earlier with V1110 cells
(0.96  0.32% CD3/GFP cells; p  0.004). This trend con-
tinued through 5 weeks post-transplant, with significantly
higher human CD3/GFP cells in spleen and BM of mice
injected with V1302 versusV1110 cells (supplemental Table 1S
and Fig. 6). At 5 weeks, 25% of V1110 cells transplanted mice
started to show low levels of CD3/GFP engraftment in
spleen (1.1 0.4%) and BM (2.4 1%). In stark contrast, 75% of
mice transplanted with V1302 cells showed heightened
engraftment in spleen (30  10%; p  0.02) and BM (11  4%;
p  0.04) (Fig. 6). Additionally, levels of the surrogate tumor
marker 2 were 2-fold higher in mice transplanted with con-
trol V1302 leukemic cells than those transplanted with V1110
cells (supplemental Fig. S2).
DISCUSSION
In this study, we showed that by silencing the expression of
the regulatory  subunit of MAT-II, we exerted significant
growth disadvantage upon human Jurkat leukemic T cells
under physiologic L-Met levels in vitro and in vivo. In the liver,
L-Met levels are 80–100 M, but in other tissues they range
from 10 to 25M. Thus, the highKm hepatic isozyme,MAT-III,
can be fully functional in that organ withoutMAT-II. By con-
trast, MAT-II, the only SAMe-synthesizing enzyme in extrahe-
patic tissue can only function when associated with its MAT-
II regulatory subunit, which plays an important role in
lowering MAT-II Km L-Met to values close to physiological
L-Met levels outside the liver (26, 29, 43, 50). Without the 
subunit, MAT-II would function at minimal capacity and
would not be able to provide normal extrahepatic cells with
adequate SAMe levels needed for their growth and survival. In
resting human T cells, MAT-II is expressed at low levels, and
mitogenic activation of these cells does not induce further
expression of this subunit; by contrast, MAT-II is constitu-
tively expressed at a much higher level in established and pri-
mary leukemic T cells (4, 5). Induction of MAT-II expression
has been reported in several types of cancer andhas been shown
to confer a proliferative advantage to human hepatomas (44).
The role of MAT-II in leukemic cells is even more crucial
because leukemic T cells, both freshly explanted ALL-2 cells
and the Jurkat cell line, utilize SAMe at significantly higher
rates than normal resting or activated T cells (4, 5). The consti-
tutive high expression ofMAT-II in leukemic cells allows high
levels of SAMe synthesis needed to meet the growth require-
ments of malignant cells. In our quest to diminish SAMe in
leukemic cells, it was unreasonable to target theMAT-II2 cat-
alytic subunit, because that would be quite detrimental and
toxic to normal cells that do not express the hepatic MAT-I/III
isozyme, i.e. themajority of extrahepatic cells. However, target-
ing MAT-II expression seemed much more appropriate and
practical, because this would not block SAMe synthesis com-
pletely but would reduce it to where the rapid growth and pro-
liferation of malignant lymphocytes and possibly other cancer-
ous cells can no longer be sustained.
We succeeded in silencing the MAT-II regulatory subunit
without significantly affecting the expression of the MAT-II2
subunit. Under these conditions, our in vitro and in vivo studies
provided strong evidence thatMAT-II ablation is detrimental
to the growth ofmalignant T cells and that this is directly due to
drastic reductions in SAMe levels needed to support their rapid
growth. Inasmuch as it is quite feasible tomodulate L-Met levels
in vivo through dietary control (45), we believe these results are
of particular interest, especially in the context of our quest to
eventually translate these research findings into clinical appli-
cations. Indeed, there is a large body of evidence that the growth
of several types of tumors is dependent on high L-Met and that
L-Met deprivation causes cell cycle arrest in the G2 phase (46,
47). Several clinical studies demonstrated that diminishing
L-Met in cancer patients by maintaining them on a Met- or
choline-free diet and/or administering methioninase exerts
selective growth disadvantage pressure on cancer cells in vitro
and in vivo, inducing mitotic and cell cycle arrest, apoptotic
FIGURE 5. Differential rescue of Jurkat cells  MAT-II expression by
incrementally increasing L-Met levels in culture. Untransduced and
V1302- and V1110-transduced Jurkat cells (5  106) were cultured at 10 M
L-Met for 6 days, and then L-Met was raised to either 20 M (A) or 50 M (B).
Viable cells were counted over 15 days, with the addition of fresh medium
every 3 days. V1110 cells ceased to grow when L-Met was raised to 20 M and
exhibited diminished growth even at 50 M. *, p  0.05; **, p  0.01; ***, p 
0.001.
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death, and widespread necrosis in tumors (48). Induction of
Jurkat cells apoptosis and death consequent to silencingMAT-
II is also in agreement with previous studies showing
increased apoptosis and necrosis of tumor cells cultured in the
absence of L-Met (1, 49). We observed significant apoptosis in
Jurkat cells lacking MAT-II at physiologic L-Met levels, and
this indicates that direct depletion of SAMemay bemore effec-
tive than L-Met depletion in inducing tumor cell apoptosis in
vivo. We believe that targeting MAT-II expression in combi-
nation with restricting dietary L-Met alone or in conjunction
with chemotherapeutic agents may prove to be a powerful
approach in the treatment of certain
bloodmalignancies, and we are cur-
rently exploring these possibilities.
The growth of Jurkat cells with
and without MAT-II expression
was reduced at 10 M compared
with 20 M L-Met; however, when
we attempted to rescue these cells
by incrementally increasing L-Met
levels in culture, we found that the
growth of cells expressingMAT-II
was fully restored at 20 M, whereas
cells lacking MAT-II could not be
rescued at this concentration. Even
at unphysiologically high 50 M
L-Met we still observed significant
apoptosis in cells lacking MAT-II.
We therefore predict that it may be
possible to adjust L-Met levels in
vivo in a way that would rescue nor-
mal cells while still inducing death
and apoptosis of leukemic cells that
do not express this important regu-
latory subunit.
We ruled out the possibility that
our in vitro observations are due to
culture artifacts, because when we
compared the ability of Jurkat cells
that do anddonot expressMAT-II
to engraft and survive in an in vivo
environment of physiologic L-Met
levels in our hyperimmune defi-
cient NOD/ScidIL-2Rnull mouse
model, we found significant differ-
ences in the in vivo tumor growth
and engraftment, even in the
absence of host immune rejection
inasmuch as these mice were not
reconstituted with a human
immune system (41). Control trans-
duced Jurkat cells grew well in this
mouse model, whereas cells lacking
MAT-II expression showed signif-
icant diminution in engraftment for
up to 5 weeks post-transplant.
Although these results are very
promising, we are currently design-
ing studies to treat leukemic cells in vivo, after they have
engrafted.
In summary, we had predicted that an approach that targets
SAMe metabolism would provide a good adjunctive therapeu-
tic tool for the treatment of leukemia because of the their exces-
sive requirement for this central metabolic compound. Our in
vivo data suggest that this approach, by itself, may have a more
drastic effect on diminishing leukemic cell growth than we had
originally anticipated. The stark difference in the in vivo sur-
vival and engraftment between the V1110- and V1302-trans-
duced cells in mice lacking proper immune defenses lead us to
FIGURE 6. MAT-II ablation diminishes leukemic cell growth in vivo. Hyperimmune-deficient NOD/Scid
IL-2Rnull mice were irradiated with 3.5GY 24 h prior to intraperitoneal transplant with 15  106 of the indicated
cells. Controls included irradiated but not injected mice and V1302 transplanted mice. Tumor engraftment
and growth were monitored by measuring % human CD3/GFP cells in mice spleens and bone marrow at 4
and 5 weeks post-transplant with either control V1302 or V1110 cells. Flow cytometry histograms of CD3/
GFP in spleen (A) or bone marrow (B) 5 weeks post-transplant. C, GFP expression in whole spleens of same
mice prior to processing their splenocytes. D, number of mice engrafted with V1302 or V1110 leukemic cells at
4 and 5 weeks post-transplant. E and F show % CD3/GFP cells in spleens (E) or bone marrow (F) of mice
transplanted with either V1302 or V1110 leukemic cells, 5 weeks post-transplant. The statistical differences
were calculated using a Mann-Whitney test. *, p  0.05; **, p  0.01; ***, p  0.001.
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be even more optimistic that it will be possible to generate tar-
geted therapeutics and dietary protocols to selectively diminish
the growth of malignant lymphocytes with little or no effect on
normal cells.
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